The recombinant vaccines market is positioned for strong growth from 2026 to 2034 as vaccine development continues to shift toward safer, more targeted, scalable, and technologically advanced platforms. Recombinant vaccines are produced using genetic engineering techniques that enable selected antigens or proteins from a pathogen to be expressed in host systems such as yeast, bacteria,...